Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Zogenix, an Emeryville, California–based rare-disease therapy specialist, will pay $250 million to acquire Modis Therapeutics, a start-up focused on rare genetic diseases. Modis’s lead candidate is MT1621, a deoxynucleoside substrate enhancement therapy in late-stage development for the treatment of thymidine kinase 2 deficiency, an often fatal mitochondrial DNA depletion disorder that primarily affects children. Modis was formed in 2016 and raised $30 million in series A funding less than a year ago.
This article has been sent to the following recipient: